Bayesian Capital Management, LP Editas Medicine, Inc. Transaction History

Bayesian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $171,532 - $270,108	24,400 New	24,400 $181,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $215,904 - $290,472	31,200 New	31,200 $243,000
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $43,586 - $71,486	-6,200 Reduced 26.84%	16,900 $122,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $47,424 - $75,297	-5,700 Reduced 19.79%	23,100 $204,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $71,744 - $114,578	5,900 Added 25.76%	28,800 $353,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $228,771 - $488,915	22,900 New	22,900 $271,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $223,073 - $340,869	-8,402 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $329,946 - $612,841	8,402 New	8,402 $345,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.